GleamWall
中文EN

SPRO Spero Therapeutics, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1701108 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY2.5%
TTM net income YoY32.7%
TTM EPS YoY36.7%
Revenue 3-yr CAGR-18.8%
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-67.3%
Net margin-71.0%
FCF margin—
EBITDA margin—

Returns

ROE-216.4%
ROA-35.9%
ROIC (approx.)—
Asset turnover0.51x

Leverage & solvency

Liabilities / assets99.3%
Debt / equity0.00x
Current ratio1.92x
Interest coverage—

Cash quality & payout

Operating cash flow / net income1.37x
Accruals ratio13.3%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31
Income statement
Revenue$66.80M$47.98M
R&D expense$38.47M$96.76M
SG&A expense$21.18M$23.70M
Operating income$6.31M-$73.36M
Pretax income$8.83M-$68.57M
Income tax$261,000$0
Net income$8.57M-$68.57M
EBITDA$6.31M-$73.36M
EPS (basic)0.15-1.27
EPS (diluted)0.15-1.27
Weighted avg. shares (diluted)59.04M54.04M
Balance sheet
Cash & equivalents$40.27M$52.89M
Current assets$67.29M$107.28M
PP&E, net—$0
Total assets$68.92M$110.54M
Current liabilities$8.87M$49.07M
Total liabilities$9.90M$64.42M
Shareholders' equity$59.02M$46.12M
Shares outstanding56.41M54.59M
Cash flow statement
Operating cash flow-$12.62M-$23.44M
Financing cash flow—$0
Depreciation & amortization$0$2,000
Stock-based compensation$4.33M$7.79M

Free plan shows the latest 2 periods; Pro shows all 11 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.